News Image

Why NYSE:PFE is a Top Pick for Dividend Investors.

By Mill Chart

Last update: Oct 9, 2023

Consider PFIZER INC (NYSE:PFE) as a top pick for dividend investors, identified by our stock screening tool. NYSE:PFE shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.

A Closer Look at Dividend for NYSE:PFE

ChartMill assigns a Dividend Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing various dividend elements, such as yield, historical performance, dividend growth, and sustainability. NYSE:PFE has been awarded a 8 for its dividend quality:

  • With a Yearly Dividend Yield of 4.90%, PFE is a good candidate for dividend investing.
  • PFE's Dividend Yield is rather good when compared to the industry average which is at 3.93. PFE pays more dividend than 97.14% of the companies in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.76.
  • PFE has paid a dividend for at least 10 years, which is a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

Health Assessment of NYSE:PFE

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:PFE has earned a 5 out of 10:

  • With a decent Altman-Z score value of 2.67, PFE is doing good in the industry, outperforming 73.33% of the companies in the same industry.
  • PFE's Debt to FCF ratio of 6.13 is amongst the best of the industry. PFE outperforms 84.76% of its industry peers.
  • PFE has a Current Ratio of 2.12. This indicates that PFE is financially healthy and has no problem in meeting its short term obligations.

Analyzing Profitability Metrics

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:PFE has earned a 8 out of 10:

  • PFE's Return On Assets of 9.75% is amongst the best of the industry. PFE outperforms 90.95% of its industry peers.
  • Looking at the Return On Equity, with a value of 21.68%, PFE belongs to the top of the industry, outperforming 91.90% of the companies in the same industry.
  • The Return On Invested Capital of PFE (11.96%) is better than 90.00% of its industry peers.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • PFE has a Profit Margin of 27.55%. This is amongst the best in the industry. PFE outperforms 94.76% of its industry peers.
  • Looking at the Operating Margin, with a value of 31.21%, PFE belongs to the top of the industry, outperforming 95.71% of the companies in the same industry.
  • PFE's Operating Margin has improved in the last couple of years.
  • PFE's Gross Margin of 68.78% is fine compared to the rest of the industry. PFE outperforms 74.29% of its industry peers.

More Best Dividend stocks can be found in our Best Dividend screener.

Check the latest full fundamental report of PFE for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

PFIZER INC

NYSE:PFE (4/26/2024, 7:09:35 PM)

After market: 25.45 +0.05 (+0.2%)

25.4

+0.14 (+0.55%)

PFE News

News Image6 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Image14 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image18 hours ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image2 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

News Image3 days ago - Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

News Image3 days ago - Pfizer Inc.U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
PFE Links
Follow us for more